Get API key
Reporting owner · Q3 2026 · CIK 1883840

RA Capital Nexus Fund III, L.P.: insider trades.

RA Capital Nexus Fund III, L.P. reported 32 non-derivative transactions on 14 SEC ownership filings in Q3 2026: 17 open-market purchases ($12.1M) and 4 sales ($85.3M), across 6 companies.

Transactions
32
Purchases (P)
17
Sales (S)
4
Companies
6
Name as filed
RA Capital Nexus Fund III, L.P.

Companies

CompanyRelationshipTransactions
Artiva Biotherapeutics, Inc. (ARTV)Director, TenPercentOwner11
Freenome, Inc. (FRNM)Director, TenPercentOwner7
Parabilis Medicines, Inc. (PBLS)Director, TenPercentOwner6
Climb Bio, Inc. (CLYM)Director, TenPercentOwner4
Sionna Therapeutics, Inc. (SION)Director, TenPercentOwner2
Septerna, Inc. (SEPN)Director, TenPercentOwner2

Transactions

32 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-09-28Climb Bio, Inc.M10,000$7.8930,000Form 4
2026-09-28Climb Bio, Inc.M40,000$1.2970,000Form 4
2026-09-28Climb Bio, Inc.M10,000$3.4610,000Form 4
2026-09-28Climb Bio, Inc.M10,000$320,000Form 4
2026-09-17Sionna Therapeutics, Inc.S3,415,011$6.323,482,612Form 4
2026-09-17Sionna Therapeutics, Inc.S33,800$7.463,448,812Form 4
2026-08-12Septerna, Inc.S746,500$42.54,777,415Form 4
2026-08-12Septerna, Inc.S746,500$42.5725,443Form 4
2026-07-31Artiva Biotherapeutics, Inc.P24,944$9.9317,329,570Form 4
2026-07-29Artiva Biotherapeutics, Inc.P20,824$9.9917,304,626Form 4
2026-07-24Artiva Biotherapeutics, Inc.P41,319$9.9917,283,802Form 4
2026-07-23Artiva Biotherapeutics, Inc.P59,880$9.9617,242,483Form 4
2026-07-22Artiva Biotherapeutics, Inc.P84,124$9.9317,182,603Form 4
2026-07-22Parabilis Medicines, Inc.P47,250$29.7726,529,686Form 4
2026-07-21Artiva Biotherapeutics, Inc.P120,582$9.5517,098,479Form 4
2026-07-21Parabilis Medicines, Inc.P21,696$27.9626,438,209Form 4
2026-07-21Parabilis Medicines, Inc.P6,504$29.1726,444,713Form 4
2026-07-21Parabilis Medicines, Inc.P37,723$3026,482,436Form 4
2026-07-20Parabilis Medicines, Inc.P32,987$27.7226,416,513Form 4
2026-07-20Parabilis Medicines, Inc.P98,433$27.1326,383,526Form 4
2026-07-20Freenome, Inc.A6,561,711—7,311,711Form 4
2026-07-20Freenome, Inc.A970,950—970,950Form 4
2026-07-20Freenome, Inc.A553,703—553,703Form 4
2026-07-20Freenome, Inc.A908,103—908,103Form 4
2026-07-20Freenome, Inc.A367,427—367,427Form 4
2026-07-20Freenome, Inc.A4,918,411$1012,230,122Form 4
2026-07-20Freenome, Inc.A336,965$101,245,068Form 4
2026-07-17Artiva Biotherapeutics, Inc.P7,882$8.9516,977,927Form 4
2026-07-16Artiva Biotherapeutics, Inc.P152,472$8.9316,970,045Form 4
2026-07-13Artiva Biotherapeutics, Inc.P6,522$8.9416,817,543Form 4/A
2026-07-13Artiva Biotherapeutics, Inc.P6,552$8.9416,817,573Form 4
2026-07-10Artiva Biotherapeutics, Inc.P15,102$8.9716,811,021Form 4

Questions

What stock did RA Capital Nexus Fund III, L.P. buy or sell?

RA Capital Nexus Fund III, L.P. reported 32 non-derivative transactions on 14 SEC ownership filings in Q3 2026: 17 open-market purchases ($12.1M) and 4 sales ($85.3M), across 6 companies.

Is RA Capital Nexus Fund III, L.P. the same person as other filers with this name?

This page covers SEC CIK 1883840 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/ra-capital-nexus-fund-iii-l-p-1883840.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.